Sabin Vaccine Institute Names David Salisbury, Jeffrey P. Libson to Board of Trustees, Philip K. Russell Retires to Advisory Role

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that Professor David Salisbury and Jeffrey P. Libson have been named to the Board of Trustees and Retired Major General Philip K. Russell will transition from Trustee to Special Advisor after more than 25 years of service to the organization.

Sabin Vaccine Institute Receives $10M Grant to Raise Confidence in Vaccines

WASHINGTON, D.C – The Sabin Vaccine Institute (Sabin) today announced it has received a three-year grant valued at $10.4 million to strengthen vaccine acceptance. In 2019, the World Health Organization identified vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – as one of the top 10 threats to global health.

Sabin Vaccine Institute Strengthens Ebola Sudan and Marburg Vaccines Program with Additional NIAID Partnership

WASHINGTON, D.C. – The Sabin Vaccine Institute (Sabin) today announced that it has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines to be used for further clinical evaluation and outbreak preparedness and to potentially protect military, first responders, health care and laboratory workers, and other at-risk populations.

Since 2011, the Sabin Vaccine Institute (Sabin) has organized a vaccinology course for immunization managers in Latin America. Launched under the direction of Dr.

Dr. John B. Robbins died on November 27, 2019 at age 86. Dr. Robbins was the 2001 recipient of the Sabin Gold Medal for his pivotal role in the development of Hib conjugate vaccine, which is now used throughout the world.

We have entered a post-antibiotic era. That striking statement comes from last week’s landmark report from the U.S. Centers for Disease Control and Prevention (CDC).

Pages